OMDA (Omada Health, Inc.) — AI Stock Analysis & Recommendation

Research of August 18, 2026 · Healthcare / Services-Health Services

TradeFlare's AI research teams rate OMDA a BUY. The latest price is $18.30.

The research plan

• Entry: $23.75
• Target: $27.31
• Stop: $20.19
• Time horizon: weeks

The post-earnings drift signal suggests a sustained upward move over the coming weeks.

Why

The post-earnings drift signal suggests a sustained upward move over the coming weeks. Catalysts to watch: Continued post-earnings drift following a significant gap up; Strong revenue growth and high gross margins supporting the business model; Positive analyst ratings and social sentiment driven by recent financial performance. Key risks: High beta and customer concentration introduce significant systematic and specific risk; Quarterly operating cash flow has been negative, raising sustainability concerns; Forward guidance anticipates a decline in revenue and adjusted EBITDA.

What could push OMDA higher

• Continued post-earnings drift following a significant gap up.
• Strong revenue growth and high gross margins supporting the business model.
• Positive analyst ratings and social sentiment driven by recent financial performance.

Key risks for OMDA

• High beta and customer concentration introduce significant systematic and specific risk.
• Quarterly operating cash flow has been negative, raising sustainability concerns.
• Forward guidance anticipates a decline in revenue and adjusted EBITDA.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Omada Health exhibits strong revenue growth and a solid business model, supported by excellent liquidity and positive analyst sentiment. However, current unprofitability and inconsistent cash flow, coupled with a speculative valuation, create a neutral outlook. The stock is priced for significant future success, making it sensitive to execution risks.

• Strong revenue growth (43.1% YoY) and high gross margins (68.19%) indicate a robust business model and pricing power.
• Despite positive TTM operating and free cash flow, quarterly operating cash flow has been negative, raising concerns about sustainability.
• Valuation metrics (P/S 4.65x, Forward P/E 42.71x) are high, pricing in significant future growth and profitability improvements.

Technical team: Bullish

Despite some mixed signals from trend and volume analysis, the strong bullish engulfing pattern and recent breakout above resistance identified by Pattern Recognition, combined with the overall uptrend context, suggest a bullish bias. The price is currently testing immediate resistance, but a break above could lead to the next target. The risk is moderate due to the lack of strong volume confirmation and neutral momentum.

• The price is consolidating near resistance, with mixed signals from moving averages and recent price action, suggesting a neutral outlook with potential for a breakout above resistance.
• The stock is consolidating near resistance with below-average volume, suggesting a neutral outlook with potential for a move towards support if resistance holds.
• The price is consolidating near resistance with mixed signals from indicators, suggesting a neutral short-term outlook.

Sentiment team: Bullish

Omada Health (OMDA) exhibits strong and improving bullish sentiment across news, social media, and professional analyst views, primarily driven by exceptional Q2 earnings and raised guidance. While concerns around forward guidance and insider selling exist, the overwhelming positive catalysts and retail interest suggest continued upward momentum.

• Predominantly bullish sentiment driven by record Q2 2026 financial results, raised guidance, and positive analyst ratings, despite some concerns regarding forward guidance and insider selling. (Score: 0.146)
• Strong positive sentiment driven by record Q2 earnings, raised guidance, favorable analyst ratings, and strategic growth initiatives, with retail investors showing significant buying interest. (Score: 0.35)
• Strong positive sentiment driven by robust earnings, optimistic analyst ratings, and strategic growth initiatives, though insider selling warrants monitoring. (Consensus: Positive)

Risk team: High

OMDA presents a high-risk profile due to significant systematic and company-specific risks, compounded by high volatility. The substantial customer concentration and negative financial metrics are key concerns, necessitating a small position size and robust risk management.

• High Systematic Risk (Beta): OMDA exhibits a high beta (1.45-2.06), indicating significant sensitivity to overall market movements and thus substantial systematic risk.
• Customer Concentration: Significant revenue reliance (66% from two Cigna-affiliated entities as of Q3 2025) exposes Omada to contract renegotiations, client strategy shifts, or loss of major customers.
• High Realized Volatility & Deep Drawdown: OMDA exhibits high realized volatility (20d annualized at 91.4%) and a deep 1-year drawdown (-59.15%), signifying substantial downside risk and potential for large losses.

OMDA at a glance

Market value	$1.3B
Price / earnings	87.0
Revenue growth (year over year)	47.6%
Profit margin	1.4%
Debt / equity	0.00

Every AI call on OMDA since August 10, 2026, and what happened next (5 calls) →

Research of August 18, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.